Gablofen (baclofen – intrathecal) for Muscle Spasms in Multiple Sclerosis

Gablofen (intrathecal baclofen) is a U.S. Food and Drug Administration (FDA) approved therapy for treatment of severe spasms caused by problems in the brain or spine in adults and children over age 4. It is designed for people with diseases such as multiple sclerosis (MS) who can not tolerate baclofen by mouth or do not experience relief from tablets.

Intrathecal baclofen therapy (ITB) is an established and widely accepted treatment option. Because it is administered directly into the intrathecal space (injected), the results are better at lower doses than oral medications, and with fewer adverse effects.

ITB therapy consists of a pump with a chamber that is placed by a surgeon under the skin of the stomach. It is connected to the intrathecal space by a small tube. The chamber is filled with liquid baclofen. The pump is programmed to distribute the medicine around the clock for controlling spasticity as needed.

This medicine has a black box warning that appears on the prescription drug’s label to call attention to serious or life-threatening risks. Abrupt discontinuation of injected Gablofen may cause high fever, altered mental status, an increase in spasms, and muscle rigidity. In rare cases, abruptly stopping the medication has led to organ failure and death. Careful attention to programming, monitoring the pump, refill scheduling, and pump alarm care is needed in order to avoid abrupt discontinuation of the drug.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

Sativex Eased MS Spasticity as an Add-on Therapy

Sativex (nabiximols), an oral spray that contains cannabis extracts, was found effective as an add-on therapy for easing spasticity in adult multiple sclerosis (MS) patients who failed to respond to other anti-spastic treatments, a real-world study from Belgium reports. Overall, about 74% patients reported easing of spasticity — muscle stiffness or spasms —after 12 weeks of treatment, defined as […]

Medical Cannabis in Greece Will Be Sold Under Brand Name Panaxir

Medical cannabis made by Panaxia Labs Israel will be marketed and distributed in Greece by Leriva Group, under a recent agreement between the two companies and pending a marketing authorization in the country. The product will be sold under the brand name Panaxir. The companies expect to start selling the first Panaxir products in 2022 […]

More Trials Needed to Clarify Benefits of Alzheimer’s Therapy Memantine in MS

Treatment of up to a year with memantine — an approved therapy for Alzheimer’s disease — failed to prevent cognitive decline and disability, and to significantly reduce fatigue and spasticity in adults with multiple sclerosis (MS), a review of published studies shows. The therapy, sold under the brand name Namenda, works by preventing glutamate — a nerve-signaling molecule previously […]

GW Pharma Plans More Clinical Trials for Sativex

GW Pharmaceuticals is planning to continue recruiting patients into two pivotal Phase 3 clinical trials of Sativex (nabiximols), an oral spray that contains cannabis extracts and is being investigated as a potential add-on therapy for people with multiple sclerosis (MS) and spasticity. The company also is planning to launch three additional clinical trials in the U.S. […]

Phase 3 Trial of Sativex, Cannabis Extract Treatment for MS Spasticity, Opens in US

A Phase 3 trial is underway in the U.S. to assess the safety and efficacy of Sativex (nabiximols), an oral spray that contains cannabis extracts, in treating spasticity — muscle stiffness or spasms — associated with multiple sclerosis (MS). Sativex, by GW Pharmaceuticals, is available in 25 countries — including most of Europe and Canada — as […]

FDA Will Review Arbaclofen ER, Potential Oral Therapy for MS Spasticity

The U.S. Food and Drug Administration (FDA) has agreed to review  Osmotica Pharmaceuticals‘ amended request for the approval of arbaclofen extended release (ER) tablets to treat spasticity in people with multiple sclerosis (MS), the company announced. The regulatory agency found that the new drug application addressed all issues raised in a July 2016 action letter response to the […]

Trial of Cannabis Derivatives in Treating MS Spasticity to Open in Canada

The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested CA$1.5 million to open a clinical trial that will investigate the potential of two cannabis derivatives — cannabidiol (CBD) and tetrahydrocannabinol (THC) — in treating spasticity (muscle stiffness) and other symptoms of multiple sclerosis (MS). The money, worth about […]

Osmotica Amends NDA for Arbaclofen ER to Treat MS Spasticity

Osmotica Pharmaceuticals has submitted an amended new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of arbaclofen extended release (ER) tablets for the treatment of spasticity in people with multiple sclerosis (MS). Arbaclofen ER (brand name Ontinua), is an extended release formulation of arbaclofen, a compound similar to the muscle […]

Spasticity Scales May Not Reflect Sativex Benefits in MS Patients, Study Suggests

Sativex (nabiximols) eases spasticity-associated symptoms in multiple sclerosis (MS) patients, including those with no significant improvements in a validated spasticity scale, according to a large study from Italy. The findings support previous studies suggesting that spasticity scales may not be enough to evaluate patients’ responses to Sativex and to reflect the therapy’s overall benefits beyond spasticity itself. […]

The Multiple Sclerosis Podcast


Survey Icon

Video